Physician profile
Smita Kumar
NPI 1578981544
$1,424.29
in general payments reported to CMS, 2019-2025
21 companies · $186 in 2025
The $186 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.29 · 2021: $81.74 · 2022: $173 · 2023: $492 · 2024: $403 · 2025: $186.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,080.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $362.74 | 2022-2025 | Minimed 780g |
| Novo Nordisk INC | $176.67 | 2019-2025 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $121.66 | 2019-2021 | |
| Amgen INC. | $114.09 | 2022-2024 | Tepezza |
| Dexcom, INC. | $106.18 | 2021-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $86.12 | 2021-2023 | Jardiance, Mounjaro |
| Cequr Corporation | $72.43 | 2023-2024 | Cequr Simplicity |
| Insulet Corporation | $72.04 | 2023-2024 | Omnipod |
| Xeris Pharmaceuticals, INC. | $58.00 | 2022-2023 | Gvoke Hypopen |
| Ascendis Pharma Endocrinology INC | $49.18 | 2023-2025 | Yorvipath |
| Sanofi-Aventis U.S. LLC | $36.68 | 2022-2023 | |
| Corcept Therapeutics | $22.71 | 2024 | Korlym |
| Kyowa Kirin, INC. | $20.08 | 2024 | Crysvita |
| Bayer Healthcare Pharmaceuticals INC. | $20.08 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.90 | 2024 | Jardiance, Synjardy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $17.20 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Halozyme INC | $15.33 | 2023 | |
| Radius Health, INC. | $14.26 | 2023 | |
| Novartis Pharmaceuticals Corporation | $13.99 | 2025 | |
| Sequel Med Tech, LLC | $13.87 | 2025 | Twiist |
| Pfizer INC. | $13.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smita Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.